Ruxolitinib plus decitabine in post-MPN AML

The outcomes of patients with post-myeloproliferative neoplasm acute myeloid leukemia (post-MPN AML) are poor, with no standard therapy. In this interview, Farhad Ravandi, MD, from the University of T... Author: VJHemOnc Added: 02/09/2018
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts